Clinical Trial Update: A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma [Phase 2]

View source ↗

Summary

Phase II trial of nivolumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• nivolumab (nivolumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Smoldering Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2023-06-13